SEC Form 4 · accession 0001012975-18-001273
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vipin K Garg
Officer — President and CEO · Director
Period of report
Nov 30, 2018
Accepted (ET)
Dec 4, 2018 · 4:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326190
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001F1,F2 | Nov 30, 2018 | A | 322,907 | $0.00 | A | 322,907 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (option to buy)F3 | $3.59 | Nov 30, 2018 | A | 211,486 | A | — | Nov 30, 2028 | Common Stock, par value $0.0001 | 211,486 | 211,486 | D |
| Stock Options (option to buy)F4 | $3.59 | Nov 30, 2018 | A | 111,421 | A | — | Nov 30, 2028 | Common Stock, par value $0.0001 | 111,421 | 111,421 | D |
Explanation of responses
- F1One-fourth of the restricted shares will vest on the one-year anniversary of the grant date and thereafter 1/48th of the restricted shares will vest monthly, such that the restricted shares will be fully vested on the fourth anniversary of the grant date, generally subject to Dr. Garg's continued employment with Altimmune on the applicable vesting date.
- F2Represents a grant of restricted stock pursuant to the Company's 2018 Inducement Grant Plan.
- F3One-fourth of the shares underlying the stock option will vest on the one-year anniversary of the grant date and thereafter 1/48th of the shares underlying the stock option will vest monthly, such that the shares underlying the stock option will be fully vested on the fourth anniversary of the grant date, generally subject to Dr. Garg's continued employment with Altimmune on the applicable vesting date.
- F4One-fourth of the shares underlying the stock option will vest on the one-year anniversary of the grant date and thereafter 1/48th of the shares underlying the stock option will vest monthly commencing on January 1, 2020, such that the shares underlying the stock option will be fully vested on December 1, 2022, generally subject to Dr. Garg's continued employment with Altimmune on the applicable vesting date.